Staidson BioPharm(SZ:300204) 智通财经网·2025-09-09 11:28Fundraising and Investment - Shuyatian plans to raise no more than 1.253 billion yuan through a private placement for innovative drug research and development projects and to supplement working capital [1] - Sanbo Brain Science intends to invest 57 million yuan in a fund focused on brain science, which aims to raise a total of 300 million yuan [5] Clinical Trials and Product Development - Taiji Group's subsidiary received approval for clinical trials of Semaglutide injection for type 2 diabetes, with a cumulative R&D investment of approximately 44.1834 million yuan [2] Production and Operations - Zhongjin Gold announced that its subsidiary in Inner Mongolia has resumed production, stating that the previous suspension did not significantly impact overall operations and performance [3] Shareholding Changes - Xibu Gold reported that its shareholder, Tulu Fan Jinyuan Mining Co., reduced its stake by 1% from September 8 to September 9, completing the reduction plan [4] - Various companies reported changes in shareholding, including Shen Keda and Yongxin Optical, with plans for both increases and decreases in shareholdings [7] Major Contracts and Projects - Apac Co. received a total contract amount of 514 million yuan for brake and EPB projects [8] - Jiangnan Water and Ruina Intelligent also reported significant contract wins, with amounts of 368 million yuan and 225 million yuan respectively [8]